@article{ab6dd04f17c74e71ab731a341bdc428a,
title = "Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype",
abstract = "Objective: To compare the clinical phenotype of patients with chronic migraine (CM) to patients with new daily persistent headache of the chronic migraine subtype (NDPH-CM). Methods: A study was conducted of CM (n = 257) and NDPH-CM (n = 76) from a tertiary headache center in the UK, and in the US of patients with daily CM (n = 60) and NDPH-CM (n = 22). Results: From the UK cohort, the age of first headache onset was lower in CM (mean ± SD: 16 ± 12 years) than in NDPH-CM (mean ± SD: 23 ± 14 years; p < 0.001). There was a greater number of associated migrainous symptoms in CM compared to NDPH-CM (median and interquartile range: 6, 5–8 vs. 5, 4–7; p < 0.001). A family history of headache was more common in CM compared to NDPH-CM (82%, 202/248, vs. 53%, 31/59; p < 0.001). In the US cohort there were no differences. Osmophobia (B = −1.08; p = 0.002) and older age at presentation to the clinic (B = −0.06; p = 0.001) were negative predictors of NDPH-CM. Conclusion: NDPH-CM is relatively less migrainous than CM in the UK cohort. Family history of headache is less common in NDPH-CM, with negative predictors for NDPH-CM including osmophobia and older age of presentation to the clinic. More work is required to understand the chronic migraine phenotype of new daily persistent headache.",
keywords = "chronic migraine, medication overuse headache, new daily persistent headache",
author = "Karthik Nagaraj and Wei, {Diana Y.} and Francesca Puledda and Weng, {Hsing Yu} and Sadaf Waheed and Nicolas Vandenbussche and Ong, {Jonathan J.Y.} and Goadsby, {Peter J.}",
note = "Funding Information: Dr. Nagaraj reports no conflicts of interest. Dr. Wei reports no conflicts of interest. Dr. Puledda reports no conflicts of interest. Dr. Weng reports no conflicts of interest. Ms. Waheed reports no conflicts of interest. Dr. Vandenbussche has received honoraria from Allergan/Abbvie, Novartis, and Teva Pharmaceuticals. Dr. Jonathan Ong has received honoraria from Novartis, Teva, Lundbeck, and DKSH (Singapore). Dr. Goadsby reports personal fees from Aeon Biopharma, grants and personal fees from Amgen, personal fees from Allergan/Abbvie, personal fees from Biohaven Pharmaceuticals Inc., grants from Celgene, grants and personal fees from CoolTech LLC, personal fees from Dr Reddy's, personal fees from Eli Lilly and Company, personal fees from Epalex, personal fees from GlaxoSmithKline, personal fees from Impel Neuropharma, personal fees from Lundbeck, personal fees from Novartis, personal fees from Pfizer, personal fees from Praxis, personal fees from Sanofi, personal fees from Satsuma, personal fees from Teva Pharmaceuticals, outside the submitted work; in addition, Dr. Goadsby has a patent Magnetic stimulation for headache licensed to eNeura without fee and fees for advice through Gerson Lehrman Group and Guidepoint, and fees for educational materials from UptoDate, Omnia Education, WebMD, and fees for publishing from Oxford University Press, Massachusetts Medical Society, and for medicolegal advice in headache. Publisher Copyright: {\textcopyright} 2022 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society.",
year = "2022",
month = jul,
day = "1",
doi = "10.1111/head.14362",
language = "English",
volume = "62",
pages = "828--838",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "7",
}